Trial Profile
A phase 2b, multicenter, randomized, double-blind, parallel-group, placebo-controlled trial evaluating the efficacy and safety of dose regimens with oral tofacitinib in the treatment of subjects with moderate-to-severe chronic plaque psoriasis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Nov 2020
Price :
$35
*
At a glance
- Drugs Tofacitinib (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Sponsors Pfizer
- 19 Nov 2020 Results of Bayesian network meta analysis assessing the relative efficacy and safety of tofacitinib administration (5 and 10 mg) twice daily in psoriasis patients published in the International Journal of Clinical Pharmacology and Therapeutics
- 12 Mar 2016 Pooled analysis (n=3431) of 5 trials [NCT00678210, NCT01276639, NCT01309737, NCT01241591, NCT01186744] were presented at the 117th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
- 02 Dec 2013 Results published in the Journal of Dermatological Treatment.